Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2006, Article ID 17898, 7 pages
Research Communication

Circulating Total and Active Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinases-1 in Patients with Systemic Lupus Erythomatosus

1Department of Dermatology and Venerology, Medical University of Lodz, Krzemieniecka 5, Lodz 94-017, Poland
2Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital in Lodz, Pabianicka 62, Lodz 93-513, Poland
3Department of Immunology and Infectious Biology, University of Lodz, Banacha 12/16, Lodz 90-237, Poland

Received 1 September 2005; Accepted 20 October 2005

Copyright © 2006 Ewa Robak et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


We investigated the serum concentration of total metalloproteinase-9 (tMPP-9), active MMP-9 (aMMP-9), and tissue inhibitor of metalloproteinase-1 (TIMP-1) in a group of 41 patients with SLE and 20 healthy controls. Serum levels of tMMP-9 and TIMP-1 were assessed by an enzyme-linked immunosorbent assay (ELISA) and aMMP-9 by fluorometric assay. The tMMP-9 level was lower in SLE patients (mean 262 ng/mL) than in healthy volunteers (mean 325 ng/mL) (P=.048). Similarly, aMMP-9 level was lower in SLE patients (mean 121 ng/mL) than in control group (mean 169 ng/mL) (P=.0355) and lower in active SLE (mean 54 ng/mL) than in inactive disease (mean 99 ng/mL) (P=.033). TIMP-1 level was also lower in SLE patients (mean 181 ng/mL) than in control group (mean 233 ng/mL) (P=.004). In SLE patients, a positive correlation was found between tMMP-9 and aMMP-9 (ρ=0.568; P=.001). We also found a positive correlation of tMMP-9 and TIMP-1 with VEGF concentrations (ρ=0.450, P=.005 and ρ=0.387; P=.018, resp). tMMP-9, aMMP-9, and TIMP-1 serum levels are lower in SLE patients than in healthy control group.